Suppr超能文献

一清双解胶囊与片剂治疗热袭肺卫证急性上呼吸道感染的多中心、随机、对照、双盲双模拟试验

[A multiple center, randomized, controlled, double-blinded and double-dummy trial of Yiqing Shuangjie Capsule and Tablet in treating acute upper respiratory tract infection with the syndrome of heat attacking the lung and Weifen].

作者信息

Wang Lei, Zhang Rui-Ming, Zhao Yan-Ling, Feng Guo-Xiang, Pan Ding-Ju, Huang Xi-Yuan, Li Ting-Qian

机构信息

Department of Integrated Chinese and Western Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan Provice, China.

出版信息

Zhong Xi Yi Jie He Xue Bao. 2008 Feb;6(2):139-47. doi: 10.3736/jcim20080207.

Abstract

OBJECTIVE

To evaluate the efficacy and safety of Yiqing Shuangjie Capsule and Tablet in treating acute upper respiratory tract infection with wind-warm syndrome.

METHODS

The multiple center, double-blinded, double-dummy and randomized controlled method was conducted. Three hundred and sixty patients were randomly divided into the treatment group A (n=120, treated with Yiqing Shuangjie Capsule and Chaihuang analogues), treatment group B (n=120, treated with Yiqing Shuangjie Tablet and Chaihuang analogues) and the control group (n=120, treated with Chaihuang Tablet and Yiqing Shuangjie Capsule analogues). Every drug was administered 3 pills each time. Patients in the three groups were all treated for 5 days and three times daily. The accumulated scores of syndrome, clinical symptoms, adverse effect and body temperature were recorded before and after the treatment. The safety indexes, such as routine tests of blood, urine and stool, hepatic and renal function tests and electrocardiogram (ECG) were taken before and after the treatment.

RESULTS

Three cases were excluded and eighteen cases lost to follow-up. There were 343 patients who entered to the intention-to-treat (ITT) analysis and 339 patients fitted in the per-protocol population set (PPS) analysis. After treatment, the therapeutic effects of respiratory tract infection were calculated by ITT and PPS analysis respectively. The rates of total obvious effect were 84.96% and 87.27% respectively in the treatment group A, and the total response rates were 96.46% and 97.27% respectively. The rates of total obvious effect were 85.47% and 86.20% respectively in the treatment group B, and the total response rates were 97.45% and 97.41% respectively. In the control group, the rates of total obvious effect both were 72.57%, and the total response rates both were 99.12%. There was significant difference among the three groups (P<0.05). The effects of traditional Chinese medicine syndrome were also detected by ITT and PPS analysis respectively. In the treatment group A, the total obvious effect rates were 84.07% and 85.46% respectively, and the total response rates were 96.46% and 97.27% respectively. In the treatment group B, the rates of total obvious effect were 88.89% and 89.65% respectively, and the total response rates were 97.44% and 97.41% respectively. In the control group, the rates of total obvious effect both were 72.57%, and total response rates both were 99.12%. There was also statistical significant difference among the three groups (P<0.05). ITT and PPS analysis had the same results. No adverse effect was found in the trial.

CONCLUSION

Yiqing Shuangjie Capsule and Tablet are effective and safe in treating acute upper respiratory tract infection of wind heat syndrome without obvious adverse effect.

摘要

目的

评价一清双解胶囊与片剂治疗急性上呼吸道感染风热证的有效性与安全性。

方法

采用多中心、双盲、双模拟、随机对照试验方法。将360例患者随机分为治疗组A(n = 120,服用一清双解胶囊及柴黄类模拟剂)、治疗组B(n = 120,服用一清双解片及柴黄类模拟剂)和对照组(n = 120,服用柴黄片及一清双解胶囊模拟剂)。每次各药均服用3片。三组患者均治疗5天,每日3次。记录治疗前后证候、临床症状、不良反应及体温的积分。治疗前后进行血、尿、便常规检查、肝肾功能检查及心电图(ECG)等安全性指标检测。

结果

剔除3例,失访18例。进入意向性分析(ITT)343例,符合符合方案集(PPS)分析339例。治疗后分别采用ITT分析和PPS分析呼吸道感染疗效。治疗组A总显效率分别为84.96%和87.27%,总有效率分别为96.46%和97.27%。治疗组B总显效率分别为85.47%和86.20%,总有效率分别为97.45%和97.41%。对照组总显效率均为72.57%,总有效率均为99.12%。三组比较差异有统计学意义(P<0.05)。分别采用ITT分析和PPS分析中医证候疗效。治疗组A总显效率分别为84.07%和85.46%,总有效率分别为96.46%和97.27%。治疗组B总显效率分别为88.89%和89.65%,总有效率分别为97.44%和97.41%。对照组总显效率均为72.57%,总有效率均为99.12%。三组比较差异有统计学意义(P<0.05)。ITT分析与PPS分析结果一致。试验过程中未发现不良反应。

结论

一清双解胶囊与片剂治疗急性上呼吸道感染风热证疗效确切、安全,未发现明显不良反应。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验